| All patients (n = 485) | Alive (n = 326) | Dead (n = 159) | p-value |
---|---|---|---|---|
Demographics | ||||
 Age (years) | 71·6 ± 16·3 | 68·4 ± 17·4 | 78·1 ± 11·5 | < 0·001 |
 Male sex [n(%)] | 259 (53·4) | 168 (51·5) | 91 (57·3) | 0·24 |
 BMI (kg/m2) | 26·3 (22·1–30·8) | 26·7 (22·2–31·4) | 25·5 (21·9–29·9) | 0·13 |
 BAME [n(%)] | 73 (15·4) | 59 (18·6) | 14 (8·9) | 0·006 |
 Clinical Frailty Scale | 5 (3–6) | 3 (2–6) | 6 (3–7) | < 0·001 |
Co-morbidities | ||||
 HFrEF [n(%)] | 59 (12·2) | 31 (9·5) | 28 (17·6) | 0·010 |
 IHD [n(%)] | 69 (14·2) | 46 (14·1) | 23 (14·5) | 0·92 |
 Hypertension [n(%)] | 222 (45·8) | 155 (47·5) | 67 (42·1) | 0·26 |
 AF [n(%)] | 97 (20·0) | 52 (16·0) | 45 (28·3) | 0·001 |
 Diabetes mellitus [n(%)] | 147 (30·3) | 90 (27·6) | 57 (35·8) | 0·064 |
 Stroke/TIA [n(%)] | 53 (10·9) | 32 (9·8) | 21 (13·2) | 0·26 |
 CKD [n(%)] | 119 (24·5) | 71 (21·8) | 48 (30·2) | 0·043 |
 COPD [n(%)] | 69 (14·2) | 37 (11·3) | 32 (20·1) | 0·009 |
 Malignancy [n(%)] | 37 (7·6) | 23 (7·1) | 14 (8·8) | 0·50 |
Medications | ||||
 ACEi [n(%)] | 84 (17·3) | 57 (17·5) | 27 (17·0) | 0·89 |
 ARB [n(%)] | 41 (8·5) | 31 (9·5) | 10 (6·3) | 0·23 |
 BB [n(%)] | 113 (23·3) | 75 (23·0) | 38 (23·9) | 0·83 |
 CCB [n(%)] | 80 (16·5) | 57 (17·5) | 23 (14·5) | 0·40 |
 Loop diuretic [n(%)] | 74 (15·3) | 47 (14·4) | 27 (17·0) | 0·46 |
 MRA [n(%)] | 18 (3·7) | 12 (3·7) | 6 (3·8) | 0·96 |
 Statin [n(%)] | 200 (41·2) | 136 (41·7) | 64 (40·3) | 0·76 |
 Antiplatelet [n(%)] | 115 (23·7) | 75 (23·0) | 40 (25·2) | 0·60 |
 Anticoagulant [n(%)] | 67 (13·8) | 38 (11·7) | 29 (18·2) | 0·049 |
 Metformin [n(%)] | 61 (12·6) | 39 (12·0) | 22 (13·8) | 0·56 |
 Sulphonylurea [n(%)] | 23 (4·7) | 18 (5·7) | 5 (3·2) | 0·23 |
 Corticosteroid [n(%)] | 24 (4·9) | 14 (4·3) | 10 (6·4) | 0·34 |
 Immunosuppression [n(%)] | 22 (4·5) | 13 (4·0) | 9 (5·7) | 0·41 |